^
    Back
    Association details:
    Biomarker:IL6 elevation
    Cancer:Small Cell Lung Cancer
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Oncoimmunology
    Title:

    Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

    Published date:
    03/27/2019
    Excerpt:
    ...evaluated the potential predictive role of cytokines in patients treated with ipilimumab….while high IL-6 and TNF-alpha predicted resistance…Blood-based biomarkers are convenient for patients, and our results support prospective validation of cytokines as predictive biomarkers for ipilimumab in SCLC....
    DOI:
    10.1080/2162402X.2019.1593810